Novotech, the global full-service clinical Contract Research Organization (CRO), has published its latest whitepaper, offering in-depth analysis and emerging trends and advancements within the rapidly evolving field of cell and gene therapies. The report provides critical insights into the growth of clinical trials, innovations and strategic opportunities, shaping the future of this field.
Key Highlights from the Report:
- Global Clinical Trial Expansion:
- Over 1,500 drug candidates in development across phases 0 to III.
- CAR-T therapies account for 32% of the pipeline, primarily targeting hematological cancers.
- The global trial landscape experienced a 32.5% growth from 2019 to 2023, with Asia-Pacific leading in trial activity (44% of all trials).
- Oncology Focus:
- CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and hematological malignancies.
- Significant attention on gastrointestinal tract and lung cancers, as well as hematological cancers like diffuse large B-cell lymphoma (DLBCL).
- Geographic Leadership:
- Asia-Pacific: Strong growth driven by China, which leads with 56% of the region's cell and gene trials.
- North America: The U.S. dominates with 85% of the trials.
- Europe: The UK, Spain, and Germany are key players.
- Technological Advancements:
- AI and Contract Development and Manufacturing Organizations (CDMOs) are transforming the cell and gene therapy landscape, improving manufacturing efficiency and trial scalability.
- Patient Recruitment Trends:
- Faster recruitment in Asia-Pacific (16.07 months) compared to the U.S. (21.15 months), with the region showing higher enrollment efficiency.
- Investment Growth:
- A significant rise in venture capital for cell and gene therapies peaked in 2021, with sustained funding for start-ups and growth-stage companies.
Novotech’s whitepaper highlights the significant potential of cell and gene therapies, particularly in oncology, and outlines opportunities for increased collaboration in global clinical trials.
Download the full report to explore the complete clinical landscape and discover how Novotech can accelerate your research efforts.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.
Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
For more information or to speak to an expert team member visit: https://novotech-cro.com/talk-to-an-expert